PHARMACOKINETIC/PHARMACODYNAMIC ANALYSIS OF HUMAN ANTI-C1S ANTIBODY (TNT009) AND CLASSICAL COMPLEMENT PATHWAY (CP) ACTIVITY

被引：0
|
作者：
Jilma, B. [1 ]
Gilbert, J. [2 ]
Nix, D. [2 ]
Chang, C. [3 ]
Beliveau, M. [3 ]
Marier, J. [3 ]
机构：
[1] Med Univ Vienna, Vienna, Austria
[2] True North Therapeut Inc, San Francisco, CA USA
[3] Certara Strateg Consulting, Montreal, PQ, Canada
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2017年 / 101卷 / S1期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PII-018
引用
收藏
页码：S58 / S58
页数：1
相关论文
共 33 条
  • [31] Highly specific inhibition of C1q globular-head binding to human IgG: A novel approach to control and regulate the classical complement pathway using an engineered single chain antibody variable fragment
    Hwang, Hee Young
    Duvall, Marcus R.
    Tomlinson, Stephen
    Boackle, Robert J.
    MOLECULAR IMMUNOLOGY, 2008, 45 (09) : 2570 - 2580
  • [32] The anti-human leukocyte antigen-DR monoclonal antibody 1D09C3 activates the mitochondrial cell death pathway and exerts a potent antitumor activity in lymphoma-bearing nonobese diabetic/severe combined Immunodeficient mice
    Carlo-Stella, C
    Di Nicola, M
    Turco, MC
    Cleris, L
    Lavazza, C
    Longoni, P
    Milanesi, M
    Magni, M
    Ammirante, M
    Leone, A
    Nagy, Z
    Gioffrè, WR
    Formelli, F
    Gianni, AM
    CANCER RESEARCH, 2006, 66 (03) : 1799 - 1808
  • [33] The human complement receptor type 2 (CR2)/CR1 fusion protein TT32, a targeted inhibitor of the classical and alternative pathway C3 convertases, prevents arthritis in active immunization and passive transfer models and acts by CR2-dependent targeting of CR1 regulatory activity
    Holers, Michael
    Banda, Nirmal
    Mehta, Gaurav
    Fridkis-Hareli, Masha
    Or, Eran
    Storek, Michael
    Altman, Richard
    Johnson, Krista
    Katti, Suresh
    IMMUNOBIOLOGY, 2012, 217 (11) : 1210 - 1210
1234